EUA
Emergency Use Authorization; an FDA mechanism permitting use of a medical product during an emergency without full approval.
As defined in Vinay Prasad on the Pandemic
Where it comes up · 3
- Zeynep Tufekci2 claims
- Vinay Prasad on the Pandemic2 claims
- 214 - A Conversation With Siddhartha Mukherjee2 claims
Most important claims · 6 of 6Search all claims for “EUA” →
- The single biggest US error was that for about 40 days there was no FDA-approved working test for the virus: the CDC's initial test worked but a faulty probe caused false positives when batches were scaled out to public health labs, while academic labs that had developed working tests (like Alex Greninger's at University of Washington) faced slow FDA/CDC licensing—creating a critical blind period during which the infection spread undetected.214 - A Conversation With Siddhartha Mukherjee
- Caution around vaccine approval is warranted because it is vaccination, not vaccines, that saves lives; even a scientifically sound vaccine can undermine public confidence and uptake if any unexpected problem is overlooked, making the slightest screw-up potentially dramatic and counterproductive.Zeynep Tufekci
- Rather than a trigger-happy FDA, what is needed is a 'dial up, dial down' system where in a pandemic the FDA proactively pre-vets and pre-authorizes high-caliber academic laboratories during peacetime, so that when its own test fails it can immediately deploy validated interim tests from those labs rather than passively waiting for applications.214 - A Conversation With Siddhartha Mukherjee
- Keeping COVID vaccines under emergency use authorization rather than full approval, despite a strong safety profile from over a billion doses, paradoxically makes people think they are experimental and holds back necessary measures like employer mandates, since employers cannot reasonably force a not-fully-approved product.Zeynep Tufekci
- As you move down to lower-risk populations and additional doses, the benefit signal shrinks, requiring larger and larger randomized trials to detect it; yet the regulatory system has demanded less and less data as it has moved along to boosters and second boosters.Vinay Prasad on the Pandemic
- For younger ages the FDA used 'immuno-bridging'—requiring only that the vaccine produce antibody levels comparable to older ages—rather than proving reduction in symptomatic or severe disease, and large outcome trials were feasible (citing Salk's 400,000-person polio trial and Pfizer's $100B revenue) and could have enrolled a million eager parents.Vinay Prasad on the Pandemic